Skip to main content

Table 4 Ratios between affected and unaffected households' income and expenditure: linear regression models

From: Health and economic impact of HIV/AIDS on South African households: a cohort study

Outcome

Crude model

Adjusted for household demography and employment*

Adjusted for household demography, employment, morbidity and mortality**

 

Ratio Affected: Unaffected

(95% CI)

P

Ratio Affected: Unaffected

(95% CI)

P

Ratio Affected: Unaffected

(95% CI)

P

Baseline

         

Household income

0.71

(0.57 – 0.88)

0.002

0.80

(0.65 – 0.97)

0.024

0.84

(0.65 – 2.09)

0.17

Income per person

0.61

(0.49 – 0.76)

<0.001

0.75

(0.62 – 0.89)

0.002

0.85

(0.68 – 0.48)

0.18

Adult equivalent income per person

0.65

(0.52 – 0.80)

<0.001

0.77

(0.64 – 0.92)

0.004

0.85

(0.67 – 1.07)

0.16

Household expenditure

0.78

(0.64 – 0.95)

0.013

0.82

(0.68 – 0.99)

0.036

0.89

(0.70 – 1.14)

0.31

Expenditure per person

0.68

(0.56 – 0.83)

<0.001

0.78

(0.66 – 0.47)

0.05

0.92

(0.74 – 1.12)

0.42

Expenditure per adult equivalent

0.72

(0.59 – 0.87)

0.001

0.80

(0.67 – 0.94)

0.009

0.90

(0.73 – 1.14)

0.36

Follow up#

         

Household income

0.92

(0.77 – 2.50)

0.35

0.91

(0.77 – 1.07)

0.25

0.94

(0.75 – 1.17)

0.56

Income per person

0.90

(0.76 – 1.07)

0.24

0.89

(0.75 – 1.05)

0.17

0.95

(0.76 – 1.19)

0.68

Adult equivalent income

0.90

(0.76 – 1.07)

0.24

0.89

(0.76 – 1.05)

0.16

0.94

(0.76 – 1.18)

0.61

Household expenditure

0.85

(0.74 – 0.97)

0.02

0.85

(0.75 – 0.98)

0.02

0.88

(0.73 – 1.05)

0.16

Expenditure per person

0.85

(0.74 – 0.98)

0.03

0.86

(0.75 – 0.99)

0.04

0.92

(0.77 – 1.11)

0.38

Expenditure per adult equivalent

0.85

(0.74 – 0.97)

0.02

0.85

(0.75 – 0.98)

0.02

0.90

(0.76 – 1.08)

0.26

  1. # Adjusted for the respective baseline income or expenditure variable in all follow up models * Adjusted for urban or rural location, age and gender composition and percentage of household members employed. ** Adjusted further for baseline morbidity and mortality and, for follow up analyses, mortality and morbidity at follow up